Age-Related Macular Degeneration: Epidemiology and Optimal Treatment

ISSN： 1170-229X

Source： Drugs & Aging, Vol.19, Iss.2, 2002-02, pp. : 101-133

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New therapies for the treatment of age-related macular degeneration

By Sarrafizadeh R. Trese M.T.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 3, 2000-03 ,pp. : 333-341

Informa Healthcare

Access to resources Recommend Favorite

Treatment and Prevention of Age‐Related Macular Degeneration

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 1, 2004-03 ,pp. : 53-57

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K. Jones Mechelle L. Halpern Michael T.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite

Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration

By Stewart Michael W

Expert Review of Clinical Pharmacology, Vol. 6, Iss. 2, 2013-03 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Current and Future Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration

By Grant M. Comer

Drugs & Aging, Vol. 21, Iss. 15, 2004-01 ,pp. : 967-992

Adis International

Access to resources Recommend Favorite